Nephrology
Latest News
Antiseptic as good as antibiotics for preventing recurrent UTI
Using methenamine hippurate as an alternative could play an important role in helping to tackle the global problem of increasing antibiotic...
From the Journals
Community genetic testing prompts behavior change in patients
“These two measurements – the change in blood pressure and increased kidney function tests – act as hallmarks for detecting beneficial lifestyle...
Conference Coverage
Finerenone + SGLT2 inhibitor of benefit in diabetes with CKD?
Results from FIDELITY, a prespecified analysis of data from two pivotal trials of finerenone, hints of an additive benefit with SGLT2 inhibitors...
Commentary
What is the healthiest salt for you?
The key to which salt is healthiest depends on the person. Our bodies need some sodium to function, just not in large amounts.
From the Journals
Biomarkers predict cardiovascular risk in chronic kidney disease patients
New models to stratify atherosclerotic cardiovascular disease risk may improve shared decision-making.
Latest News
No COVID vax, no transplant: Unfair or good medicine?
Is removing them from the list unfair and cruel, or simply business as usual?
From the Journals
Allopurinol found safe in patients with concomitant gout, CKD
Despite earlier concerns, a study has found no sign of increased mortality with allopurinol therapy in patients with gout and chronic kidney...
From the Journals
Death, kidney injury rates in ICU patients similar with saline, multielectrolyte solution
“A lot of the treatments we use in critical care have not been properly evaluated,” said Dr. Simon Finfer.
From the Journals
HIV+ patients get good outcomes after kidney or liver transplant
New research further supports the inclusion of people with HIV in transplant resource allocation.
From the Journals
Little evidence to support use of pricey repository corticotropin
Conference Coverage
Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.